Alkermes Pre-Paid Expenses 2010-2024 | ALKS

Alkermes pre-paid expenses for the quarter ending September 30, 2024 were $0.094B, a 118.81% increase year-over-year.

  • Alkermes pre-paid expenses for 2023 were $0.098B, a 138.25% increase from 2022.
  • Alkermes pre-paid expenses for 2022 were $0.041B, a 15.86% decline from 2021.
  • Alkermes pre-paid expenses for 2021 were $0.049B, a 19.28% decline from 2020.

Alkermes Pre-Paid Expenses 2010-2024 | ALKS

  • Alkermes pre-paid expenses for 2023 were $0.098B, a 138.25% increase from 2022.
  • Alkermes pre-paid expenses for 2022 were $0.041B, a 15.86% decline from 2021.
  • Alkermes pre-paid expenses for 2021 were $0.049B, a 19.28% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$151.4B
Bristol Myers Squibb (BMY)$119.8B
Gilead Sciences (GILD)$119.1B
Vertex Pharmaceuticals (VRTX)$113.7B
CSL (CSLLY)$83.5B
Regeneron Pharmaceuticals (REGN)$75.5B
GSK (GSK)$72.7B
Argenex SE (ARGX)$39.5B
Alnylam Pharmaceuticals (ALNY)$35.3B
BioNTech SE (BNTX)$29B
BeiGene (ONC)$22.2B
Biogen (BIIB)$21B
Illumina (ILMN)$20.9B
Moderna (MRNA)$15.7B
Incyte (INCY)$14.2B
Insmed (INSM)$14B
Intra-Cellular Therapies (ITCI)$13.5B
Genmab (GMAB)$13.1B
Genmab (GNMSF)$12.9B
BioMarin Pharmaceutical (BMRN)$12.1B
Bio-Techne Corp (TECH)$11.4B
Vaxcyte (PCVX)$11.1B
Sarepta Therapeutics (SRPT)$11B
Exact Sciences (EXAS)$10.2B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Bio-Rad Laboratories (BIO.B)$10B
QIAGEN (QGEN)$9.7B
Repligen (RGEN)$9.5B
Exelixis (EXEL)$9.4B
Roivant Sciences (ROIV)$8.1B